Takeda scouts out lenders to back its $40B-plus Shire bid

Takeda US facility
Under U.K. takeover rules, Takeda has until April 25 to bid for Shire or walk away. (Takeda)

The Shire bid Takeda’s been discussing is getting real.

The Japanese drugmakers is gauging creditors’ interest in providing loans that could help it make a bid that tops $40 billion, Reuters’ sources said. And Takeda will need some serious money; it's looking for tens of billions of dollars' worth of debt from multiple banks, the news service said, citing Kyodo News.

Among the potential creditors Takeda is consulting is its main bank, Sumitomo Mitsui Banking Corp.

Free Webinar

Building a Flexible, Challenge Resistant and Patient Centric Clinical Supply Chain

The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. In this webinar, learn the benefits of utilizing demand-led supply and direct-to-patient distribution models in the clinical supply chain, as well as how they can be used to both improve flexibility and better align with patient needs. Register today!

If Takeda wants to swallow Shire, it’s going to have to take a big bite. While industry watchers were initially skeptical the company could pull it off—especially after word that Takeda was weighing a transaction dragged down its shares and sent Shire’s soaring—analysts turned more positive last week after Takeda outlined just how much debt it was willing to take on.

“We think the deal is likely because there is willing buyer, willing sellers and room to meet both sides’ expectations,” Bernstein’s Wimal Kapada wrote to clients, adding that he sees a deal as “more likely than not.”

Meanwhile, the clock is ticking for Takeda, which could vault itself into the ranks of the world’s top drugmakers and beef up in the GI and neuroscience arenas if it can swing the Shire buy. Under U.K. takeover rules, the pharma has until April 25 to make a bid or walk away.

Read more on

Suggested Articles

In a departure from the usual approval process, the FDA says it doesn't require manufacturing inspections before weighing vaccines for emergency use.

Sanofi and Regeneron released follow-up data from a phase 3 trial for immunology blockbuster Dupixent in an eosinophilic esophagitis.

Singapore has suspended the use of two flu vaccines, from SK Bioscience and Sanofi, amid reports of deaths in South Korea after immunization.